This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.
Mammoth Biosciences developed the test in response to the COVID-19 pandemic. The company was one of one of seven chosen to receive funding through the National Institutes of Health’s RADx program to support development and commercialization of the test.
Tim Patno, vice president of product development at Mammoth Biosciences, will discuss Mammoth’s novel CRISPR-based technology as well as the company’s partnership with MilliporeSigma to manufacture its DETECTR BOOST SARS-CoV-2 Reagent Kit. Patno will discuss the steps Mammoth took to vet and choose a manufacturing partner within the context of commercializing a novel in vitro diagnostic.
Attendees will learn:
- The basic technology and platform of the CRISPR-based SARS-CoV-2 DETECTR test.
- The steps in the commercialization process of an IVD; from scope of work through to development, engineering, validation, and closing.
- Advantages of working with a commercial partner to expedite kit development and launch.